Journey Medical (DERM) Stock Price, News & Analysis

Company Overview

Journey Medical Corporation (NASDAQ: DERM) is a commercial-stage pharmaceutical company focused on developing and marketing prescription therapies for dermatological conditions. The company targets areas of significant unmet need, including acne, hyperhidrosis, fungal infections and other medical skin disorders.

Journey Medical’s product portfolio has included Qbrexza (glycopyrronium tosylate), a topical treatment for primary axillary hyperhidrosis, as well as Targadox (doxycycline hyclate) for the treatment of severe acne and Exelderm (sulconazole nitrate) for certain fungal skin infections. The company also markets additional prescription dermatology products and evaluates opportunities to acquire or commercialize therapies that complement its portfolio.

Founded in 2014, Journey Medical operates primarily in the United States and supports its products through a specialized dermatology commercial organization. The company was founded by Claude Maraoui, who has served as its president and chief executive officer. Journey Medical became a publicly traded company in 2021.

Key Stats

• Today's Range: $7.29 to $7.61
• 50-Day Range: $6.15 to $7.97
• 52-Week Range: $4.31 to $9.56
• Volume: 259,778 shs
• Average Volume: 127,954 shs
• Market Capitalization: $206.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Hold

Journey Medical Stock Analysis - MarketRank™

Journey Medical scored higher than 37% of companies evaluated by MarketBeat, and ranked 723rd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Journey Medical has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Journey Medical has a consensus price target of $14.00, representing about 91.5% upside from its current price of $7.31.

Amount of Analyst Coverage

Journey Medical has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Journey Medical are expected to grow in the coming year, from ($0.02) to $0.90 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Journey Medical is -33.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Journey Medical is -33.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Journey Medical has a P/B Ratio of 7.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.28% of the float of Journey Medical has been sold short.

Short Interest Ratio / Days to Cover

Journey Medical has a short interest ratio ("days to cover") of 17.45, which indicates bearish sentiment.

Change versus previous month

Short interest in Journey Medical has recently increased by 1.51%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Journey Medical does not currently pay a dividend.

Dividend Growth

Journey Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: N/A

News Sentiment

Journey Medical has a news sentiment score of 1.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Journey Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.53% of the stock of Journey Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

7.25% of the stock of Journey Medical is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:DERM
• Previous Symbol: NASDAQ:DERM
• CIK: 1867066
• Web: www.jmcderm.com
• Phone: 480-434-6670
• Fax: N/A
• Employees: 58
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Journey Medical: $14.00
• High Price Target: $15.00
• Low Price Target: $13.00
• Potential Upside/Downside: +91.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.43 million
• Net Margins: -8.95%
• Pretax Margin: -8.93%
• Return on Equity: -20.23%
• Return on Assets: -6.60%

Debt

• Debt-to-Equity Ratio: 0.64
• Current Ratio: 1.59
• Quick Ratio: 1.41

Sales & Book Value

• Annual Sales: $61.86 million
• Price / Sales: 3.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.96 per share
• Price / Book: 7.61

Miscellaneous

• Outstanding Shares: 28,220,000
• Free Float: 24,123,000
• Market Cap: $206.29 million
• Optionable: N/A
• Beta: 1.09